ARCH, F-Prime and Mubadala pump $200M into former Denali programsnews2025-01-08T13:00:40+00:00January 8th, 2025|Endpoints News|
Exclusive: GV-backed Prudentia launches with $7M to boost pharma dealmakingnews2025-01-08T13:00:09+00:00January 8th, 2025|Endpoints News|
Novo expands pact with Flagship’s Valo to include obesity, diabetes for $190M near-termnews2025-01-08T11:30:47+00:00January 8th, 2025|Endpoints News|
Maze files for first biotech IPO of 2025, following $115M funding boostnews2025-01-07T22:36:51+00:00January 7th, 2025|Endpoints News|
Exclusive: Avenzo picks up another ADC, this time with multi-partnered DualityBionews2025-01-07T12:00:59+00:00January 7th, 2025|Endpoints News|
Exclusive: Forbion-backed cardio biotech rebrands to RyCarma with Phase 2 plansnews2025-01-07T10:30:18+00:00January 7th, 2025|Endpoints News|
‘Microprotein’ biotech Velia, backed by TCG and Foresite, to wind downnews2025-01-06T20:00:51+00:00January 6th, 2025|Endpoints News|
Exclusive: Joe Jimenez’s Aditum Bio rings in new year with $428M third fundnews2025-01-06T16:27:24+00:00January 6th, 2025|Endpoints News|
Exclusive: AI biotech Iambic snags CFO who helped steer Recursion-Exscientia dealnews2025-01-06T11:30:05+00:00January 6th, 2025|Endpoints News|
Regeneron buys London-based ocular biotechnews2025-01-02T18:46:53+00:00January 2nd, 2025|Endpoints News|
